CD274 and neoplasm: PD-1/PD-L1 inhibitors reinstate an immune-permissive microenvironment by activating effector T cells and augmenting IFN-γ production, which in turn promotes tumor vascular normalization and potentiates T cell infiltration and cytotoxic activity (18).